EP3916392
METHODS FOR PREDICTING THERAPEUTIC BENEFIT OF ANTI-CD19 THERAPY IN PATIENTS
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
30.5.2017EP published:
1.5.2024EP application number:
21170716.1
EP translation filed:
28.5.2024Grant published:
15.6.2024EPO information:
European Patent Register
Max expiry date:
29.5.2037Expiry date:
29.5.2026Next due date:
31.5.2026
Title in English:
METHODS FOR PREDICTING THERAPEUTIC BENEFIT OF ANTI-CD19 THERAPY IN PATIENTSLanguage of the patent:
English
Timeline
Today
30.5.2017EP application
1.5.2024EP Publication
28.5.2024Translation submitted
15.6.2024Registration published
29.5.2026Expires
Owner
Name:
Incyte CorporationAddress:
1801 Augustine Cut-Off, Wilmington, DE 19803, US
Inventor
Name:
ENDELL, JanAddress:
80333 München, DE
Name:
WINDERLICH, MarkAddress:
81373 München, DE
Name:
BOXHAMMER, RainerAddress:
83059 Kolbermoor, DE
Agent
Name:
Zacco Denmark A/SAddress:
Arne Jacobsens Allé 15, DK
Priority
Number:
16171885Date:
30.5.2016Country:
EP
Classification
Categories:
G01N 33/574
Annual fees
Number
Paid
Expires
Payer
Number: 8
Paid: 4.6.2024
Expires: 29.5.2025
Payer: Árnason Faktor ehf.
Number: 9
Paid: 30.5.2025
Expires: 29.5.2026
Payer: Árnason Faktor ehf.